(Q38480437)

3 September 2017

1 reference

title

Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers (English)

1 reference

3 September 2017

Koichi Ichimura

1

1 reference

3 September 2017

Yoshitaka Narita

series ordinal

2

1 reference

3 September 2017

Cynthia E Hawkins

series ordinal

3

1 reference

3 September 2017

publication date

15 May 2015

1 reference

3 September 2017

published in

Acta Neuropathologica

1 reference

3 September 2017

volume

129

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

789-808

1 reference

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Assessment of the pathological grade of astrocytic gliomas using an MRI score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Adult supratentorial low-grade glioma: long-term experience at a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The p53 gene and its role in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

COLD PCR HRM: a highly sensitive detection method for IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Cigarette smoking, alcohol intake, and risk of glioma in the NIH-AARP Diet and Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The interface between glial progenitors and gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Alternative lengthening of telomeres: remodeling the telomere architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

A 4-gene signature associated with clinical outcome in high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Alpha thalassaemia-mental retardation, X linked

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Molecular subtypes of glioblastoma are relevant to lower grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Expanding the spectrum of IDH1 mutations in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Molecular markers in low-grade gliomas: predictive or prognostic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

What do we know about IDH1/2 mutations so far, and how do we use it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

TERT promoter mutations in familial and sporadic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Highly recurrent TERT promoter mutations in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The CpG island methylator phenotype: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mitotic recombination of chromosome 17 in astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The genetic landscape of anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Cellular defense against singlet oxygen-induced oxidative damage by cytosolic NADP+-dependent isocitrate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Molecular classification of low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH2 mutations in patients with D-2-hydroxyglutaric aciduria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

An in vivo patient-derived model of endogenous IDH1-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

21 January 2018

p53 mutations in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Current knowledge and treatment strategies for grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Prognostic significance of imaging contrast enhancement for WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Natural history of incidental World Health Organization grade II gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Natural history and surgical management of incidentally discovered low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Molecular diagnostics of gliomas: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

A vaccine targeting mutant IDH1 induces antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mutational landscape and clonal architecture in grade II and III gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Interlaboratory comparison of IDH mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

Cell of origin for malignant gliomas and its implication in therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-015-1439-7

10.1007/S00401-015-1439-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1009925351

0 references

1 reference